You may have heard about Ozempic, Wegovy and Mounjaro. It’s tough to miss the online chatter, the ads on TV and all the news coverage. They are part of a class of drugs originally designed to treat diabetes, and all three have been shown to help people lose significant amounts of weight. That’s leading to big sales for drug companies and helping change the way we think about weight loss. WSJ’s Ariana Aspuru digs into how these drugs work, the big money involved and what it means for millions of Americans who meet the criteria for obesity.
Further reading:
Pill for Obesity Has Wall Street Salivating
Will Ozempic Change ‘Body Positivity’ for Good?
No More Shots: Pill Versions of Ozempic-Like Drugs Are Coming
The Drugs That Are Gaining on Ozempic
Learn more about your ad choices. Visit megaphone.fm/adchoices